skip to main content

Coeliac disease and medicines — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardGastrointestinal TherapeuticsCoeliac disease and medicinesGPhC CRA

In February 2026, a dermatology service plans to initiate isotretinoin for a 17-year-old with severe treatment-resistant acne. One appropriately expert lead prescriber has assessed the patient. Which statement reflects the current MHRA position?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — One expert prescriber may initiate; updated safety materials and monitoring still apply

From 22 January 2026 the MHRA removed the mandatory second-prescriber agreement for patients under 18. That change did not remove specialist initiation or the broader risk-minimisation programme. Updated acknowledgement materials, the required patient information video and existing counselling and monitoring of mental health, sexual function and pregnancy risk continue. A signature alone does not permit unrestricted GP initiation, and pharmacists cannot initiate treatment solely because screening tests are satisfactory.

Reference: MHRA: Isotretinoin changes to prescribing guidance and risk-minimisation measures. https://www.gov.uk/drug-safety-update/isotretinoin-changes-to-prescribing-guidance-and-additional-risk-minimisation-measures